Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

1 Apr 2017

Abstract excerpt

Abstract High-throughput genomic analyses may improve outcomes in patients with advanced cancers. MOSCATO 01 is a prospective clinical trial evaluating the clinical benefit of this approach. Nucleic acids were extracted from fresh-frozen tumor biopsies and analyzed by array comparative genomic hybridization, next-generation sequencing, and RNA sequencing. The primary objective was to evaluate clinical benefit as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Treatments and Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28365644
DOI: 10.1158/2159-8290.cd-16-1396

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 TrialPMID 28365644Read ↗

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsSemantic proximity Read ↗

Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors.Semantic proximity Read ↗

Precision oncology based on omics data: The NCT Heidelberg experienceSemantic proximity Read ↗

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options: the PRECODE study protocolSemantic proximity Read ↗

Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialSemantic proximity Read ↗

Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.Semantic proximity Read ↗

Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced CancersSemantic proximity Read ↗

Whole-genome and transcriptome analysis enhances precision cancer treatment options.Semantic proximity Read ↗

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.Semantic proximity Read ↗

Novel clinical trial designs emerging from the molecular reclassification of cancerSemantic proximity Read ↗

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.Semantic proximity Read ↗

Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.